NLRP3, the inflammasome and COVID-19 infection

被引：12
|
作者：
Yin, Maureen [1 ]
Marrone, Laura [2 ,3 ]
Peace, Christian G. [1 ]
O'Neill, Luke A. J. [1 ]
机构：
[1] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin 2, Ireland
[2] CEINGE Biotecnol Avanzate, I-80145 Naples, Italy
[3] Feder II Univ Naples, Dipartimento Med Mol & Biotecnol Med DMMBM, I-80131 Naples, Italy
来源：
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE | 2023年 / 116卷 / 07期
基金：
爱尔兰科学基金会; 欧洲研究理事会; 英国惠康基金;
关键词：
HOSPITALIZED-PATIENTS; INTERLEUKIN-1; HYPERINFLAMMATION; ANAKINRA; COLCHICINE; PNEUMONIA; BLOCKADE; THERAPY; RELEASE; DISEASE;
D O I：
10.1093/qjmed/hcad011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Severe coronavirus disease 2019 (COVID-19) is characterized by respiratory failure, shock or multiorgan dysfunction, often accompanied by systemic hyperinflammation and dysregulated cytokine release. These features are linked to the intense and rapid stimulation of the innate immune response. The NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a central player in inflammatory macrophage activation which via caspase-1 activation leads to the release of the mature forms of the proinflammatory cytokines interleukin (IL)-1 beta and IL-18, and via cleavage of Gasdermin D pyroptosis, an inflammatory form of cell death. Here, we discuss the role of NLRP3 activation in COVID-19 and clinical trials currently underway to target NLRP3 to treat severe COVID-19.
引用
收藏
页码：502 / 507
页数：6
相关论文
共 50 条
  • [1] Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
    Bonaventura, Aldo
    Vecchie, Alessandra
    Dagna, Lorenzo
    Tangianu, Flavio
    Abbate, Antonio
    Dentali, Francesco
    INFLAMMATION RESEARCH, 2022, 71 (03) : 293 - 307
  • [2] Severe COVID-19: NLRP3 Inflammasome Dysregulated
    van den Berg, Daan F.
    te Velde, Anje A.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [3] The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies
    Zhao, Ni
    Di, Bin
    Xu, Li-li
    CYTOKINE & GROWTH FACTOR REVIEWS, 2021, 61 : 2 - 15
  • [4] Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
    Potere, Nicola
    Del Buono, Marco Giuseppe
    Caricchio, Roberto
    Cremer, Paul C.
    Vecchie, Alessandra
    Porreca, Ettore
    Dalla Gasperina, Daniela
    Dentali, Francesco
    Abbate, Antonio
    Bonaventura, Aldo
    EBIOMEDICINE, 2022, 85
  • [5] Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
    Aldo Bonaventura
    Alessandra Vecchié
    Lorenzo Dagna
    Flavio Tangianu
    Antonio Abbate
    Francesco Dentali
    Inflammation Research, 2022, 71 : 293 - 307
  • [6] Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients
    N. B. Amaral
    T. S. Rodrigues
    M. C. Giannini
    M. I. Lopes
    L. P. Bonjorno
    P. I. S. O. Menezes
    S. M. Dib
    S. L. G. Gigante
    M. N. Benatti
    U. C. Rezek
    L. L. Emrich-Filho
    B. A. Sousa
    S. C. L. Almeida
    R. Luppino-Assad
    F. P. Veras
    A. H. Schneider
    L. O. S. Leiria
    L. D. Cunha
    J. C. Alves-Filho
    T. M. Cunha
    E. Arruda
    C. H. Miranda
    A. Pazin-Filho
    M. Auxiliadora-Martins
    M. C. Borges
    B. A. L. Fonseca
    V. R. Bollela
    C. M. Del-Ben
    F. Q. Cunha
    R. C. Santana
    F. C. Vilar
    D. S. Zamboni
    P. Louzada-Junior
    R. D. R. Oliveira
    Inflammation Research, 2023, 72 : 895 - 899
  • [7] Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients
    Amaral, N. B.
    Rodrigues, T. S.
    Giannini, M. C.
    Lopes, M. I.
    Bonjorno, L. P.
    Menezes, P. I. S. O.
    Dib, S. M.
    Gigante, S. L. G.
    Benatti, M. N.
    Rezek, U. C.
    Emrich-Filho, L. L.
    Sousa, B. A.
    Almeida, S. C. L.
    Luppino-Assad, R.
    Veras, F. P.
    Schneider, A. H.
    Leiria, L. O. S.
    Cunha, L. D.
    Alves-Filho, J. C.
    Cunha, T. M.
    Arruda, E.
    Miranda, C. H.
    Pazin-Filho, A.
    Auxiliadora-Martins, M.
    Borges, M. C.
    Fonseca, B. A. L.
    Bollela, V. R.
    Del-Ben, C. M.
    Cunha, F. Q.
    Santana, R. C.
    Vilar, F. C.
    Zamboni, D. S.
    Louzada-Junior, P.
    Oliveira, R. D. R.
    INFLAMMATION RESEARCH, 2023, 72 (05) : 895 - 899
  • [8] The Role of NLRP3 Inflammasome in Pericarditis
    Mauro, Adolfo G.
    Bonaventura, Aldo
    Vecchie, Alessandra
    Mezzaroma, Eleonora
    Carbone, Salvatore
    Narayan, Pratyush
    Potere, Nicola
    Cannata, Antonio
    Paolini, John F.
    Bussani, Rossana
    Montecucco, Fabrizio
    Sinagra, Gianfranco
    Van Tassel, Benjamin W.
    Abbate, Antonio
    Toldo, Stefano
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2021, 6 (02): : 137 - 150
  • [9] Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19
    Saeedi-Boroujeni, Ali
    Mahmoudian-Sani, Mohammad-Reza
    Nashibi, Roohangiz
    Houshmandfar, Sheyda
    Tahmaseby Gandomkari, Sima
    Khodadadi, Ali
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2021, 43 (03) : 247 - 258
  • [10] NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity
    Amin, Saiful
    Aktar, Salma
    Rahman, Md Mijanur
    Chowdhury, Mohammed Mehadi Hassan
    MICROBES AND INFECTION, 2022, 24 (01)
12345